Intestinal Fistula Treatment Market Snapshot (2023 to 2033)
The global intestinal fistula treatment market is expected to be valued at US$ 26.64 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Intestinal Fistula Treatment is projected to grow at a CAGR of 5.8% between 2023 and 2033, totaling around US$ 46.82 Billion by 2033.
Data Points
Key Statistics
Expected Market Value for Intestinal Fistula Treatment in 2023
US$ 26.64 Billion
Projected Market Value for Intestinal Fistula Treatment in 2033
US$ 46.82 Billion
Global Growth Rate (2023 to 2033)
CAGR of 5.8%
According to the analysis of Future Market Insights, factors such as a rise in the inflammatory bowel disease (IBD) patient pool, increase in the prevalence of Crohn’s disease, approval of new biologic drugs, novel drugs pipeline, and increase in demand for application of intestinal fistula treatment in developing countries are expected to augment the growth of the intestinal fistula treatment market.
Reimbursement plans introduced by the leading players to cushion healthcare expenditure will lead to positive sentiment among patients toward effective treatment. Growth in investments in the treatment of intestinal fistula is also anticipated to help achieve high ROI, as physicians tend to prescribe these drugs for the treatment of moderate to severe intestinal fistula. In addition, the development of anti-adhesion molecules is likely to propel the adoption of integrin antagonists.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Intestinal Fistula Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for intestinal fistula treatment is projected to increase at a CAGR of 5.8% during the forecast period between 2023 and 2033, reaching a total of US$ 46.82 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.2%. According to Future Market Insights, a market research and competitive intelligence provider, the Intestinal Fistula Treatment market was valued at US$ 25.18 Billion in 2022.
The global rise in the prevalence of intestinal fistula is driving the growth of the intestinal fistula treatment market. The major cause of the disease includes inflammatory bowel diseases, which result in long-term chronic inflammation of the gastrointestinal (GI) tract without any known cause. Factors such as innovations in product development, approval of drugs, and rising inclination toward the use of biologic and biosimilar drugs are expected to boost the revenue share of intestinal fistula treatment during the forecast period. Growth in sales of intestinal fistula drugs through online, retail, and hospital pharmacies is helping companies generate more revenues. For instance, in December 2019, the FDA approved two biosimilars - adalimumab and infliximab - for the treatment of Ulcerative Colitis.
Biopharmaceutical companies have made significant investments in Research and Development activities. Large numbers of pipeline products are in different stages of clinical approvals, which are likely to commercialize over the analysis period. According to a report, around 2.5 million people in the USA suffered from inflammatory bowel disease in 2020. The prevalence of IBD among the USA population is expected to rise to around 3.5 million by 2030. Similarly, data suggest that the incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing in Europe; around 0.2% of the population of Europe suffered from IBD in 2020. This in turn is anticipated to accelerate market growth in the forthcoming years.
Which Drivers underpin Intestinal Fistula Treatment Industry Expansion?
Increasing focus on Research and Development for the Treatment of Intestinal Fistulato Fuel the Market Growth
Technological development, such as the use of single-cell RNA sequencing, is helping healthcare professionals in the treatment of intestinal fistula treatment. High-dimensional technologies such as single-cell RNA sequencing and mass cytometry have been performed on the intestinal specimens collected from patients suffering from Crohn’s disease or ulcerative colitis. Several benefits of the single-cell RNA sequencing analysis used to understand the molecular basis of the disease include the development of novel therapeutic approaches, optimizing the individual medicines, and preventing the disease.
For instance, in August 2020, The University of California and VA San Diego Healthcare System (VASDHS) used transcriptomic and antigen receptor sequencing strategies to characterize tissue and immune cell features in individuals with or without ulcerative colitis. These advancements in technology provide an unusual view of immune cell networks in health and disease. These factors are expected to escalate the growth of the intestinal fistula treatment market during the forecast period.
Rise in Awareness Regarding Intestinal Fistula to Accelerate the Market Growth
There are numerous factors that are responsible for the increasing prevalence of intestinal fistula treatment market, which are genetic predisposition, environmental triggers, and immune system disturbance, which all are results of Crohn’s Disease. The majority of the patients suffering from ulcerative colitis or Crohn’s disease have a family history of the disorder.
For instance, according to a research study conducted by Hopkins Medicine, about 10 to 15% of the patients suffering from Crohn’s disease have a family history of the disorder. Approximately 5 to 7% of the patients suffering from ulcerative colitis have a family history of the disorder.
Various government organizations are creating awareness about intestinal fistula by educating people about the symptoms, diagnosis, and treatments available for the condition. Hence, the rising awareness about the treatment options available and the increasing rate of disease diagnosis in developing countries are projected to support the market growth. Thus, the aforementioned factors are leading to increasing demand for drugs over the analysis period.
Find your sweet spots for generating winning opportunities in this market.
Which Factors are limiting the Growth of Intestinal Fistula Treatment Market?
High Cost of Intestinal Fistula Drugs to Limit the Market Growth
The high treatment cost of the intestinal fistula, including the drug cost and other costs, reducing the number of patients undergoing treatment are expected to hinder the adoption of intestinal fistula treatment in patients. Additionally, the adoption of biologics is increasing to treat the disease, but the high costs associated with biologics treatment are limiting the market growth.
For instance, according to the National Center for Biotechnology Information (NCBI), the average annual cost of Adalimumab per person is about USD 12,343 in the United Kingdom In emerging countries, such as India, China, and Russia, there is a lack of reimbursement for intestinal fistula treatment, limiting the adoption of these drugs in the region. Hence, the high cost of medications for treating the disease and the lack of reimbursement policies in developing countries are anticipated to impede market growth in the near future.
Region-wise Insights
Will North America Continue Dominance in the Global Intestinal Fistula Treatment Market?
Increase in Prevalence of Ulcerative Colitis in the Region to Fuel the Market Growth
The intestinal fistula treatment market in North Americais expected to accumulate the highest market share of 45% in 2023. Factors such as the high prevalence and increase in the incidence of ulcerative colitis and Crohn’s disease in the USA and Canada, well-established healthcare infrastructure, and high risk of lifestyle-related factors are expected to augment the regional market growth during the forecast period.
Moreover, the strong product pipeline of key players is another major factor that is anticipated to fuel the market growth in the region. For instance, according to the National Center for Biotechnology Information (NCBI), the prevalence of inflammatory bowel disease in Canada will be over 0.75% in 2021. The region is expected to hold the highest CAGR of 5.7% during the forecast period.
How Will the Growth of the Intestinal Fistula Treatment Market unfold in the Asia Pacific?
Rising Awareness Regarding Available Treatment Options in the Region to Fuel the Market Growth
The intestinal fistula treatment market in the Asia Pacificis expected to accumulate the highest market share of 44% in 2023. The intestinal treatment market in China is anticipated to grow at a significant share over the analysis period. attributed to the factors such as an increase in the intestinal fistula patient pool and a rise in the focus of manufacturers on the development of novel therapeutics.
Additionally, factors including increasing awareness about available treatment options for the disease in the region and increasing approvals for the drugs for the treatment of the disease are also expected to fuel the regional market growth. For instance, in December 2021, Eisai Co., Ltd. and Gilead Sciences, Inc. agreed to the commercialization and distribution of filgotinib, an oral, JAK1 preferential inhibitor for indications of ulcerative colitis and Crohn's disease in Asia (South Korea, Taiwan, Hong Kong, and Singapore).
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
By Drug Class, which Intestinal Fistula Treatment Category will remain prominent?
Proton-Pump Inhibitors Segment to beat Competition in Untiring Market
On the basis of drug class, proton-pump inhibitors are likely to account for 45% of all drug sales. The segment is expected to augment at a CAGR of 5.7% over the analysis period. Growth is attributed to the factors such as the fact that the PPIs inhibit acid secretion, whether promoted by histamine, acetylcholine, or gastrin.
Moreover, PPIs work by irreversibly blocking the H+/K+ ATPase enzyme or the gastric proton pump, which is found within the parietal cells of the stomach and is the final step of acid production. All these factors are expected to stimulate the segment’s growth during the forecast period.
By Distribution Channel, which Intestinal Fistula Treatment Category dominates?
Hospital Pharmacies account for the bulk of all Intestinal Fistula Treatment Medication Sales
Based on distribution channels, hospital pharmacies are expected to account for 46% of intestinal fistula treatment medication sales in 2023 and are expected to grow at a 5.6% CAGRuntil 2033. Growth is attributed to the fact that most of the major intestinal fistula treatment drugs and products are prescription products, which are available in hospital pharmacies.
Furthermore, the segment dominated the market with a significant share, attributed to reimbursement policies in developing countries, which cover the high cost of these drugs. For instance, according to Baylor Scott & White, in the USA, approximately 45% of the costs are covered by the pharmacy, including injectable drugs and others.
The Start-up Ecosystem: How key Players are opening Frontiers for Future Growth?
Intestinal Fistula Treatment Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
In June 2021, Gusto Global, a microbiome discovery platform company focused on restoring a healthy microbiome, developed novel consortia of bacteria for treating Crohn’s disease and ulcerative colitis in patients.
In April 2019, Signum Surgical, an Ireland-based startup landed more than $3 million in grants to help fund its efforts to gain U.S. and European regulatory clearance for a device intended to treat a condition that can cause fecal incontinence. The BioHealx technology is designed to treat anal fistula.
In May 2018, Oshi Health, a digital startup focused on digestive health, launched a mobile app specifically designed to help inflammatory bowel disease patients understand and manage their condition. The app has an all-in-one mobile platform with three primary aims: condition and lifestyle tracking, patient education, and active IBD management.
Who are the Leading Players in the Intestinal Fistula Treatment Market?
Prominent players in the intestinal fistula treatment market are:
Livealth BioPharma
Boehringer Ingelheim International GmbH
Pfizer Inc.
Apsolabs
AstraZeneca
Pipelinepharma
Astellas Pharma Inc.
Caspian Tamin Pharmaceutical Company
Eli Lilly
GlaxoSmithKline
Bristol-Myers Squibb
Merck & Co. KGaA
Moderna Inc.
Recent Developments:
In December 2022, Moderna, Inc., and Merck announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p value=0.0266) compared with KEYTRUDA alone.
In September 2022, Bristol Myers Squibb announced that the Phase 3 CheckMate -76K trial evaluating Opdivo (nivolumab) as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo at a pre-specified interim analysis. No new safety signals were observed at the time of the analysis.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 5.8% from 2023 to 2033
Market Value in 2023
US$ 26.64 Billion
Market Value in 2033
US$ 46.82 Billion
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug Class
Route of Administration
Distribution Channel
Region
Regions Covered
North America
Asia Pacific
Europe
Latin America
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
China
Japan
South Korea
Indonesia
Thailand
Singapore
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Livealth BioPharma
Boehringer Ingelheim International GmbH
Pfizer Inc.
Apsolabs
AstraZeneca
Pipelinepharma
Astellas Pharma Inc.
Caspian Tamin Pharmaceutical Company
Eli Lilly
GlaxoSmithKline
Bristol-Myers Squibb
Merck & Co. KGaA
Moderna Inc.
Customization
Available upon Request
Key Segments Covered in the Intestinal Fistula Treatment Industry Analysis
By Drug Class:
Anticholinergic
Proton-Pump Inhibitors
H2 Blockers
Antidiarrheals
By Route of Administration:
Oral
Parenteral
Rectal
Transdermal
Intravenous
By Distribution Channel:
Hospital Pharmacies
Clinical Pharmacies
Drug Stores
Online Pharmacies
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Frequently Asked Questions
What is Asia Pacific's Share in the Intestinal Fistula Treatment Market?
Asia Pacific is expected to accumulate a market share of 44% in 2023.
What is the Historical Outlook of the Market?
From 2018 to 2022, the market registered a CAGR of 5.8%.
What is the Growth Forecast for the Intestinal Fistula Treatment Market?
The market is likely to register a 5.8% CAGR Until 2033.
What is the Estimated Market Size by 2033?
The industry is expected to reach US$ 46.82 billion in 2033.
What is North America's Market Share?
North America is expected to accumulate a high market share of 45% in 2023.
Table of Content
1. Executive Summary | Intestinal Fistula Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Billion) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Anticholinergic
5.3.2. Proton-pump Inhibitors
5.3.3. H2 Blockers
5.3.4. Antidiarrheals
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Billion) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Parenteral
6.3.3. Rectal
6.3.4. Transdermal
6.3.5. Intravenous
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Billion) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Clinical Pharmacies
7.3.3. Drug Stores
7.3.4. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa(MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of Middle East and Africa(MEA)
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class
14.1.2.2. By Route of Administration
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class
14.2.2.2. By Route of Administration
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class
14.3.2.2. By Route of Administration
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class
14.4.2.2. By Route of Administration
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class
14.5.2.2. By Route of Administration
14.5.2.3. By Distribution Channel
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class
14.6.2.2. By Route of Administration
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class
14.7.2.2. By Route of Administration
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class
14.8.2.2. By Route of Administration
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class
14.9.2.2. By Route of Administration
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class
14.10.2.2. By Route of Administration
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class
14.11.2.2. By Route of Administration
14.11.2.3. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class
14.12.2.2. By Route of Administration
14.12.2.3. By Distribution Channel
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class
14.13.2.2. By Route of Administration
14.13.2.3. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class
14.14.2.2. By Route of Administration
14.14.2.3. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class
14.15.2.2. By Route of Administration
14.15.2.3. By Distribution Channel
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Class
14.16.2.2. By Route of Administration
14.16.2.3. By Distribution Channel
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Class
14.17.2.2. By Route of Administration
14.17.2.3. By Distribution Channel
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Class
14.18.2.2. By Route of Administration
14.18.2.3. By Distribution Channel
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Class
14.19.2.2. By Route of Administration
14.19.2.3. By Distribution Channel
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Class
14.20.2.2. By Route of Administration
14.20.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Livealth BioPharma
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Boehringer Ingelheim International GmbH
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Pfizer
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Apsolabs
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. AstraZeneca
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Pipelinepharma
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Astellas Pharma Inc
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Caspian Tamin Pharmaceutical Company
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Eli Lilly
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. GlaxoSmithKline
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Billion) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 5: North America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033
Table 7: North America Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 9: Latin America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 13: Europe Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033
Table 15: Europe Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 17: Asia Pacific Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033
Table 19: Asia Pacific Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033
Table 20: Asia Pacific Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 21: MEA Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 22: MEA Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033
Table 23: MEA Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033
Table 24: MEA Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Billion) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Billion) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 4: Global Market Value (US$ Billion) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Billion) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 11: Global Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Billion) by Drug Class, 2023 to 2033
Figure 22: North America Market Value (US$ Billion) by Route of Administration, 2023 to 2033
Figure 23: North America Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 24: North America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 31: North America Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Billion) by Drug Class, 2023 to 2033
Figure 42: Latin America Market Value (US$ Billion) by Route of Administration, 2023 to 2033
Figure 43: Latin America Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 51: Latin America Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Billion) by Drug Class, 2023 to 2033
Figure 62: Europe Market Value (US$ Billion) by Route of Administration, 2023 to 2033
Figure 63: Europe Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 64: Europe Market Value (US$ Billion) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Europe Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Market Value (US$ Billion) by Drug Class, 2023 to 2033
Figure 82: Asia Pacific Market Value (US$ Billion) by Route of Administration, 2023 to 2033
Figure 83: Asia Pacific Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 84: Asia Pacific Market Value (US$ Billion) by Country, 2023 to 2033
Figure 85: Asia Pacific Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 91: Asia Pacific Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: Asia Pacific Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033
Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033
Figure 99: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 101: MEA Market Value (US$ Billion) by Drug Class, 2023 to 2033
Figure 102: MEA Market Value (US$ Billion) by Route of Administration, 2023 to 2033
Figure 103: MEA Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 104: MEA Market Value (US$ Billion) by Country, 2023 to 2033
Figure 105: MEA Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: MEA Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033
Figure 109: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 111: MEA Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033
Figure 112: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: MEA Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 115: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 117: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 118: MEA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 119: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
